APA (7th ed.) Citation

S, Y., K, H., K, K., H, B., S, K., & K, N. (2025). Cisplatin-induced AKI risk stratification and safety of dose reduction in urothelial carcinoma patients with renal impairment. Actas urologicas espanolas, 49(10), 501864. https://doi.org/10.1016/j.acuroe.2025.501864

Chicago Style (17th ed.) Citation

S, Yamamoto, Higa K, Kurokawa K, Bamba H, Kanaoka S, and Nakamura K. "Cisplatin-induced AKI Risk Stratification and Safety of Dose Reduction in Urothelial Carcinoma Patients with Renal Impairment." Actas Urologicas Espanolas 49, no. 10 (2025): 501864. https://doi.org/10.1016/j.acuroe.2025.501864.

MLA (9th ed.) Citation

S, Yamamoto, et al. "Cisplatin-induced AKI Risk Stratification and Safety of Dose Reduction in Urothelial Carcinoma Patients with Renal Impairment." Actas Urologicas Espanolas, vol. 49, no. 10, 2025, p. 501864, https://doi.org/10.1016/j.acuroe.2025.501864.